---

Comparison of efficacy of topical bepotastine besilate and alcaftadine in patients with vernal keratoconjunctivitis

---

Original Article

Author Details : Neha Yadav*, Sumit Sachdeva, Manisha Rathi, Sonia Chhabra, Shreay Vashisth, Dinkar Yadav

Volume : 10, Issue : 2, Year : 2024

Article Page : 319-324

https://doi.org/10.18231/j.ijceo.2024.057

Suggest article by email

Get Permission

---

Abstract

Aim: To compare efficacy of bepotastine besilate (1.5%) versus alcaftadine (0.25%) in patients with vernal keratoconjunctivitis.
Materials and Methods: This comparative, randomized, single-blind and prospective study was conducted on 100 patients diagnosed with VKC, who were allocated to receive either of the two treatment groups. Group A received Alcaftdine eye drops once daily, while Group B received bepotastine besilate twice daily for 8 weeks. The efficacy assessment was done at baseline and then at 4 and 8 weeks post-treatment using following parameters - Primary endpoints included clinical symptoms score and clinical signs score and secondary endpoint included upper tarsal conjunctival brush cytology for eosinophil count.
Results: Intra-group analysis of clinical symptoms and clinical signs score showed statistically significant reduction in both scores and eosionophil count when compared to baseline values with both the drugs. On inter-group analysis, it was found that there was no statistically significant difference between the two groups in reduction in clinical symptoms and clinical signs score and eosinophil count.
Conclusion: This study concluded that both drugs proved equally efficacious in relieving signs and symptoms of VKC. Difference in improvement of signs, symptoms, eosinophil count between both the groups drugs was not statistically significant.
 

Keywords: Bepotastine, Eosinophils, Vernal keratoconjunctivitis.

How to cite : Yadav N, Sachdeva S, Rathi M, Chhabra S, Vashisth S, Yadav D, Comparison of efficacy of topical bepotastine besilate and alcaftadine in patients with vernal keratoconjunctivitis. Indian J Clin Exp Ophthalmol 2024;10(2):319-324

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.